SCHEMBL4628517

SCHEMBL4628517

Cc1ccc(C(=O)NC(=N)Nc2ccc(OC(C)C)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.57
SCN2A Q99250 1/20 0.57
MAPT P10636 7/20 0.56
ALDH1A1 P00352 6/20 0.56
KMT2A Q03164 6/20 0.56
LMNA P02545 3/20 0.56
TP53 P04637 3/20 0.56
HSD17B10 Q99714 2/20 0.56
KDM4E B2RXH2 2/20 0.56
NLRP1 Q9C000 1/20 0.56
MCL1 Q07820 1/20 0.56
NPC1 O15118 6/20 0.56
RAB9A P51151 6/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 3/20 0.54
MEN1 O00255 3/20 0.54
ALOX15 P16050 2/20 0.52
USP2 O75604 1/20 0.52
XDH P47989 1/20 0.52
GLA P06280 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629387 0.90 NPC1 (0.61) MAPTALDH1A1KMT2ALMNATP53
SCHEMBL4628765 0.88 KMT2A (0.61) MAPTALDH1A1KMT2ALMNATP53
SCHEMBL4628741 0.86 ALDH1A1 (0.59) MAPTALDH1A1KMT2ALMNATP53
SCHEMBL3074365 0.86 NPC1 (0.67) MAPTALDH1A1KMT2ALMNAKDM4E
SCHEMBL27897904 0.84 ALDH1A1 (0.67) SCN5ASCN2AMAPTALDH1A1KMT2A
SCHEMBL4628500 0.84 LMNA (0.56) MAPTALDH1A1KMT2ALMNATP53
SCHEMBL4628446 0.82 SCN5A (0.54) SCN5ASCN2AMAPTALDH1A1KMT2A
SCHEMBL4627489 0.79 ABCB1 (0.55) MAPTALDH1A1KMT2ALMNATP53
SCHEMBL4105488 0.78 ALDH1A1 (0.70) MAPTALDH1A1KMT2ALMNATP53
SCHEMBL4629228 0.78 NPC1 (0.56) MAPTKMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN5A 1196/4885SCN2A 1613/4885MAPT 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.